Primary Objective:~• To establish the MTD and/or Recommended Phase 2 Dose (RP2D) of orally administered TP-1454 in patients with metastatic solid tumors and anal cancer.~Secondary Objectives:~To establish the pharmacokinetic (PK) profile of orally administered TP-1454~To observe patients for any evidence of antitumor activity of TP 1454 by objective radiographic assessment~To assess the safety and tolerability of TP-1454
This study will evaluate the safety and tolerability of oral TP-1454 in patients with advanced metastatic or progressive solid tumors and anal cancer.